1. P865: BIOMARKER ANALYSIS TO SUPPORT DOSE OPTIMIZATION OF IBERDOMIDE AS MONOTHERAPY AND IN COMBINATION WITH STANDARD OF CARE TREATMENTS FOR MULTIPLE MYELOMA FROM A PHASE 1/2 TRIAL. (23rd June 2022) Authors: Amatangelo, M.; Cheng, Y.; Pierceall, W.; van de Donk, N. W.; Lonial, S.; Wang, M.; Emerson, J.; Hong, K.; Maciag, P.; Peluso, T.; Gandhi, A.; Thakurta, A. Journal: HemaSphere Issue: Volume 6(2022)Supplement 3 Page Start: 758 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. THU0109 Lack of Efficacy of CCR1 Antagonist BMS-817399 in Patients with Moderate to Severe Rheumatoid Arthritis: Results of 12-Week Proof-Of-Concept Study. (10th June 2014) Authors: Kivitz, A.; Maciag, P.; Gulati, P.; Du, S.; Connolly, S.E.; Davies, P.; Li, X.; Repsher, T.; Haggerty, H.G.; Londei, M. Journal: Annals of the rheumatic diseases Issue: Volume 73:Supplement 2(2014) Page Start: 215 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗